| Literature DB >> 35300702 |
Mingzhe Yan1,2, Yanming Zhang1,2, Zhihang Wu1,3, Yifei Li1,2, Keke Dou1, Banghui Wang1,2, Yingruo Wang4, Qihui Zhou5.
Abstract
Unintended pregnancy is a global issue with serious ramifications for women, their families, and society, including abortion, infertility, and maternal death. Although existing contraceptive strategies have been widely used in people's lives, there have not been satisfactory feedbacks due to low contraceptive efficacy and related side effects (e.g., decreased sexuality, menstrual cycle disorder, and even lifelong infertility). In recent years, biomaterials-based long-acting reversible contraception has received increasing attention from the viewpoint of fundamental research and practical applications mainly owing to improved delivery routes and controlled drug delivery. This review summarizes recent progress in advanced biomaterials for long-acting reversible contraception via various delivery routes, including subcutaneous implant, transdermal patch, oral administration, vaginal ring, intrauterine device, fallopian tube occlusion, vas deferens contraception, and Intravenous administration. In addition, biomaterials, especially nanomaterials, still need to be improved and prospects for the future in contraception are mentioned.Entities:
Keywords: Biodegradable implant; Biomaterials; Controlled drug delivery; Delivery route; Long-acting reversible contraception
Mesh:
Substances:
Year: 2022 PMID: 35300702 PMCID: PMC8932341 DOI: 10.1186/s12951-022-01329-5
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Effectiveness of contraceptive methods [7]
| Method | Effectiveness | Method | Effectiveness |
|---|---|---|---|
| Female condoms | 5 | Female sterilization (tubal ligation) | 0.5 |
| Standard days method | 5 | Combined oral contraceptives | 0.3 |
| TwoDay method | 4 | Progestogen-only pills | 0.3 |
| Withdrawal | 4 | Combined contraceptive patch and combined contraceptive vaginal ring | 0.3 |
| Male condoms | 2 | Progestogen-only injectables | 0.2 |
| Emergency contraception pills | 2 | Implants | 0.1 |
| Sympto-thermal method | 1 | Male sterilization (vasectomy) | 0.1 |
| Lactational amenorrhea method | 0.9 | Monthly injectables or combined injectable contraceptives | 0.05 |
| Intrauterine device (IUD): copper-containing | 0.6 | Basal body temperature method | None |
| Intrauterine device (IUD) levonorgestrel | 0.5 | Calendar method or rhythm method | None |
Effectiveness: pregnancies per 100 women per year with consistent and correct use. None: reliable effectiveness rates are not available
Biomaterials used in contraception
| Type | Characteristics | Examples | Products | Defects | Ref. |
|---|---|---|---|---|---|
| Metallic biomaterials | Spermicidal effect and antibacterial properties | Cu (Cu2+), Iron oxide | Cu-IUD, nanoparticles | Biological toxicity of oxidation products | [ |
| Polymeric biomaterials | Adequate mechanical and physical properties, bio-inertness, and good biocompatibility | Latex, silicone, PE | Condoms, implants, IUD | Non-biodegradability and poor drug-delivery efficiency | [ |
| Composite biomaterials | Bioactive interaction and plasticity | SMA, PLGA, GDL | RISUG®, Vaginal gel | Potential foreign body reactions | [ |
| Biodegradable biomaterials | Nature source, good biodegradability, and biocompatibility | CS, β-GP | Microneedle patch | Difficulty to obtain the high purity materials | [ |
Cu: Copper; Cu2+: Copper ion; Cu-IUD: Copper-containing IUD; PE: polyethylene; IUD: intrauterine device; SMA: styrene maleic anhydride; PLGA: polylactic acid co-glycolic acid; GDL: gluconolactone; CS: chitosan; β-GP: β-sodium glycerophosphate
Fig. 1The analysis of keyword co-occurrences on biomaterials and contraception
Fig. 2The schematic illustration of advanced biomaterials applied in contraception by various routes
Fig. 3A The male hypothalamic–pituitary–gonadal axis. B The female hypothalamic–pituitary–gonadal axis
The frequent methods for contraception [38–40]
| Method | Device | Mechanism | Pros and cons |
|---|---|---|---|
| Hormonal methods | Implant | The implant is a progestin-coated silicone rod that is implanted in the woman’s upper arm by the medical professional. The progesterone in the silicone rod being released slowly prevents normal ovulation and thickens the mucus at the entrance to the uterus so that sperm cannot pass through | The implant has a high contraceptive efficiency for up to 3 years. It does not disturb sexual life during this period and allows a rapid recovery of fertility after removal. However, its earlier use may cause a reduction in menstrual blood flow or even amenorrhoea, as well as a localized sensation of abnormality on insertion, which requires professional handling. Caution should be taken in patients with severe liver disease and those at risk of blood clots |
| Patch | The patch is attached to the lower abdomen, buttocks, or upper body, where the oestrogen and progesterone are absorbed into the body through the skin, inhibiting the production of FSH and LH, thus preventing normal ovulation as well as thickening the mucus secreted at the entrance to the uterus, thus making it more difficult for sperm to pass | Compared to the implant, the patch is easy to operate and does not require professional assistance, while the fertility is recovered more quickly. Performed once a week, but with a lower contraceptive efficiency | |
| Injector | The synthetic depot medroxyprogesterone acetate (DMPA) is used to achieve contraception by intramuscular injection, preventing normal ovulation as well as thickening the mucus secreted at the entrance to the uterus, thus making it more difficult for sperm to pass | DMPA has a remarkable contraceptive efficacy and can be administered to relieve menstrual pain and prevent diseases such as ovarian and endometrial cancers. However, patients need to be injected every three months and may experience progesterone-like symptoms with initial use. Secondly, the recovery of fertility needs to wait for 18 months after stopping use. Caution should be taken in patients at risk of blood clots | |
| Progestin-only pill | The progestogen-only pill contains the hormone progesterone, which thickens the mucus at the entrance to the uterus and alters the endometrium, preventing the entry of sperm into the uterus and fertilization | The progestogen-only pill is suitable for most women, but needs to be taken every day and may cause progestogen-like symptoms on initial use | |
| Combined oral contraceptives | The combination of estrogen and progestin administered orally can prevent normal ovulation and also makes the mucus secretion from the uterine entrance sticky, more difficult for sperm to pass through | The contraceptive is highly effective when taken correctly and the combined oral administration for suitable age up to 50 years old facilitates to reduce painful menstrual periods. However, the initial use may cause strong progestin-like symptoms, e.g., breast tenderness, weight gain, reduced libido, especially in patients at risk of blood clots | |
| Vaginal ring | The vaginal ring is a plastic drug delivery platform for estrogen and progesterone that is placed in the vagina. The vaginal wall absorbs the released hormones, thereby inhibiting ovulation and controlling menstruation | The contraceptive effect may be not immediate and the ring is not easily fixed in the vagina, Besides, the pregnant and patients at risk of blood clots should be cautious to use it | |
| Intrauterine contraception | Hormonal-IUD | The IUD is divided into hormonal-IUD and Cu-IUD. Hormonal-IUD consists of plastic and progestin (e.g. LNG), which is slowly released after it is inserted into the uterus by the medical professional. Hormones can thicken the mucus entering the uterine mouth, prevent sperm from passing through, and thin the uterine wall, making it difficult for fertilized eggs to implant. Copper IUD consists of plastic and copper. Copper is toxic to sperm and changes endometrium, making it difficult for fertilized eggs to implant | The IUD provides good contraceptive effectiveness, which can be effective for 5 to 10 years. The administration has no effect on normal sexual life and the rapid recovery of fertility after removal can be achieved. However, the initial use of the device may cause side effects such as menstrual pain, irregular bleeding, and breast pain |
| Cu-IUD | |||
| Barrier methods | Condom | The condom works as a physical barrier, worn on the penis or inserted into the vagina during sex, preventing body fluids from passing | It works well when used correctly and can prevent the spread of sexually transmitted diseases. Improper use or condom breakage can lead to unwanted pregnancy, and latex has allergic potential |
| Spermicide | Spermicide in various forms (e.g. foam, gel, cream, film, suppository, or tablet) is placed in the vagina to kill sperm that are released into the vagina | Spermicide can be easily operated without significantly interrupting the sexual experience. However, it is poor contraceptive effectiveness | |
| Fertility awareness | Fertility awareness refers to avoiding sexual intercourse during the time of the menstrual cycle when the woman is most fertile | No requirement for contraception during intercourse, but a higher rate of unwanted pregnancy than other methods | |
| Withdrawal | The withdrawal refers to the removal of the penis from the vagina before ejaculation to prevent the release of sperm into the vagina | This method has a satisfying sexual experience, but has a higher rate of unwanted pregnancy because the male body fluid may still contain sperm before ejaculation | |
| Lactational amenorrhea | A lactational amenorrhea method is a form of temporary contraception in which a woman who gives birth to the fetus does not have a menstrual period, meaning that ovulation does not occur | The method can be used only if three conditions are met: (1) less than 6 months after childbirth, (2) amenorrhea, and (3) fully breastfeeding | |
| Sterilization | Tubal ligation | Sterilization is a medical treatment that permanently prevents pregnancy by blocking the pathway for ejaculation or sperm–egg binding through the vas deferens or tubal ligation | Sterilization provides permanent contraception with high safety and a low risk of unwanted pregnancy. However, it is relatively difficult or impossible to restore fertility after sterilization |
| Vasectomy |
Hormonal-IUD: hormonal intrauterine device
Fig. 4A Scanning electron microscopy (SEM) image of DMNs (LNG-HP-β-CD). B Skin penetration test of DMNs. C Detection of mechanical properties of DMNs with or without chitosan and β-GP. D Pharmacokinetic assay of LNG loaded into various groups
(Reprinted with permission from reference [30]. Copyright 2017 Elsevier, Ltd)
Fig. 5A Schematic representation of the design of the MNs with bubbly sponsorship and the interaction of application to fast convey MNs into the skin. B Rapid detachment of MNs patches from effervescent backing. C Representative images of skin, tissue section, and rat after MNs application and removal. D Structural changes of MNs before and after application and human skin reaction in 0–24 h. E The efficiency of penetration and detachment of the microneedles and Normalized erythema intensity of human skin in 0–24 h
(Reprinted with permission from reference [8]. Copyright 2019 American Association for the Advancement of Science)
Fig. 6A The design of the PDMS-based polymer matrices for oral drug delivery. B The performance evaluation of the arm includes flexural strength, interfacial tensile stability, and stability of LNG in the devices. C Detection of serum concentration of LNG in pigs administered as pills (left), three arms of PDMS (middle), and six arms of PDMS (right). D X-ray images observing the arm shapes and retention sites in the porcine stomach
(Reprinted with permission from reference [10]. Copyright 2019 American Association for the Advancement of Science)
Fig. 7A Schematic representation of the fabrication of CS-LNG microsphere in PVA hydrogel. B SEM micrograph of CS-LNG microsphere. C Schematic diagram of PVA hydrogel by hydrogen bonding and annealing. D SEM exhibition of 10% PVA hydrogels after drying and annealing. E Dissolution test observed by SEM micrograph of 10% PVA hydrogel combined with LNG-loaded chitosan microsphere. F Equilibrium swelling ratio of PVA hydrogels. G Cumulative LNG release from PVA hydrogel in vitro
(Reprinted with permission from reference [9]. Copyright 2019 American Chemical Society)
Commercial products of IUD [92–94]
| Product | Channel | Characteristics | Pearl index |
|---|---|---|---|
| CuT380A | Copper ion Cu2+ release | ① Nonhormonal, and effective emergency contraceptives ② Increased incidence of bleeding and cramping | 0–0.8 |
| Viracept | Cu2+ release | ① Lower total copper loading ② Great performance on flexibility | 0–0.45 |
| IUB | Cu2+ release | ① Shape memorized alloy ② Potential risk of expulsions and removals | 0–0.29 |
Mirena Liletta Skyla | Hormonal delivery | ① | 0–0.14 |
| GyneFix 200 | Frameless IUD | The flexible shape reduces pain and ectopic pregnancy | 1.3 |
IUB: the intrauterine ball
The development of solving the “burst-releasing” phenomenon of Cu2+
| Materials | Bio-component | Technological breakthrough | Ref. |
|---|---|---|---|
| IDM delivery system | Indomethacin | ① The initial explosion release of Cu2+ was eliminated ② The sustained release time of IDM was controlled by adjusting the number of layers of the film | [ |
| Novel Cu/PDMS nanocomposite | Nano-Cu particles | ① The distribution of Cu nanoparticles was more uniform in the PDMS matrix ② The release rate of Cu2+ became adjustable by changing the number of Cu nanoparticles | [ |
| PLGA film | The occurrence of the burst release of Cu2+ was relieved by coating PLGA on the | [ | |
| Phytocompound-based electropolymeric coating | PolyCarvCu coating | It was a strong inhibitory effect on the initial release of Cu2+ | [ |
IDM: indomethacin
Fig. 8A Macrostructure of 3D-IUD. B Cumulative release assay of estriol and estradiol from 3D-IUD. C, D SEM micrograph of surface morphology of coated pellet and filament. E, F Thermogravimetric analysis and differential scanning calorimetry of PCL-hormones composites
(Reprinted with permission from reference [115]. Copyright 2017 Public Library of Science)
Fig. 9A Schematic diagram of semi-interpenetrating polymer network composed of PCL-DA, PEG-DA, and RISUG®. B The characterizations of polymer containing cooling and heating curves, X-ray diffraction peak patterns, and thermogravimetric analysis. C Immunohistochemical evaluation of rat uterine tissues compared with control and treated groups
(Reprinted with permission from reference [129]. Copyright 2020 Elsevier, Ltd)
Fig. 10Related factors affecting the function of RISUG [144, 145]
Fig. 11The medium-term male contraceptive composite hydrogel system via physical and chemical inhibition. A Composition of the four components of the system in the tube and the dissolving process after Infrared ray irradiation. B in vitro stimulation of fertility recovery after Infrared ray irradiation. C sperm morphology analysis from vas deferens and HE staining from the cross-section of each the vasculature of three types of rats
(Reprinted with permission from reference [29]. Copyright 2019 American Chemical Society)
Fig. 12A Schematic representation of the design and SEM image of PEG@Fe3O4-50. B The testicular temperature under IONPs thermomagnetic therapy in vivo. C Schematic diagram of non-invasive contraception by intravenous injection of PEG@Fe3O4-50. D Thermal infrared images of treated mice under an alternating magnetic field
(Reprinted with permission from reference [23]. Copyright 2021 American Chemical Society)